Skip to main content
. Author manuscript; available in PMC: 2017 Apr 12.
Published in final edited form as: Circulation. 2016 Mar 2;133(15):1458–1471. doi: 10.1161/CIRCULATIONAHA.115.020678

Figure 3.

Figure 3

Stim1 silencing after TAC reverted established cardiac hypertrophy. A, Schematic timeline to study Stim1 silencing effect on TAC-induced heart failure (HF). B, Time-course of Fractional Shortening (left) and Left Ventricular Internal Diameter (right) assessed by echocardiography. d=in diastole. Sham (dotted line) vs. TAC (straight line) animals treated with AAV9.shStim1 (green) or control (white). C, Cardiac function and volumes assessed by hemodynamic measurements. Top left, End Diastolic volume (EDV). Top right, End Systolic Volume (ESV). Bottom left, Ejection Fraction (EF) and bottom right, representative pressure-volume loops in the four groups of animals. D, Time-course of Inter Ventricular Septum thickness in diastole (IVSd) assessed by echocardiography in the four groups of animals. Sham (dotted line) vs. TAC (straight line) animals treated with AAV9.shStim1 (green) or control (white). E, Heart and lung weights at the time of sacrifice. F, Left, immunofluorescence analysis of left ventricular sections (8μm) using an antibody against Vinculin (green) and Caveolin1α (red). Nuclei were stained with DAPI. Images were taken at 20X magnification. Right, quantification of cardiomyocyte area. N≥6 per groups. * p<0.05, ** p<0.01, *** p<0.0001.